Loading company…
Renalytix develops AI-based diagnostic tests to assess kidney disease risk and guide care.
Renalytix develops diagnostic tools for early detection and personalized treatment of kidney disease. Its KidneyIntelX™ platform assesses the risk of declining kidney function, and its KidneyIntelX.dkd test is designed to predict chronic kidney disease progression over five years. Founded in 2018, the company is based in New York, US, and trades as RENX on the London Stock Exchange and RNLX on NASDAQ. In April 2024, DB Capital Partners acquired 2.6 million shares for USD 0.375 each in a USD 1 million PIPE transaction.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in